Symbiotec Pharmalab Ltd

Symbiotec Pharmalab Ltd has announced the closure of its trading window for dealing in the company's securities. This closure is effective from September 01, 2026, and will remain in effect until 48 hours after the declaration of the unaudited financial results for the quarter ended June 30, 2026. The decision aligns with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. The specific date for the board meeting to approve these financial results will be communicated separately.

Symbiotec Pharmalab Ltd has filed an intimation under Regulation 8(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015. The company has enclosed its Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information, framed under Regulation 8(1) of the SEBI PIT Regulations. This disclosure is for informational purposes and to ensure compliance with regulatory requirements regarding the handling of sensitive company information.

Symbiotec Pharmalab Ltd has disclosed the individuals authorized to determine the materiality of events or information and make necessary disclosures to stock exchanges, as per SEBI Listing Regulations. The Chairman & Managing Director, Anil Satwani, along with the Chief Financial Officer, Raghavender Ramachandran, and the Company Secretary & Compliance Officer, Salil Jain, are empowered to make these crucial determinations. This move ensures compliance with regulatory requirements for timely and accurate information dissemination.